BriaCell Therapeutics (BriaCell Therapeutics) EV-to-EBITDA : -1.09 (As of Apr. 29, 2024)

BriaCell Therapeutics EV-to-EBITDA Chart

BriaCell Therapeutics Annual Data
	Trend	Jul14	Jul15	Jul16	Jul17	Jul18	Jul19	Jul20	Jul21	Jul22	Jul23
EV-to-EBITDA		Get a 7-Day Free Trial					-2.12	-1.38	-1.53	-2.22	-4.18

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EV-to-EBITDA	Get a 7-Day Free Trial															-4.12	-5.68	-4.18	-2.74	-2.36

Competitive Comparison of BriaCell Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, BriaCell Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BriaCell Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's EV-to-EBITDA falls into.

BriaCell Therapeutics EV-to-EBITDA Calculation

BriaCell Therapeutics's EV-to-EBITDA for today is calculated as:

BriaCell Therapeutics's current Enterprise Value is $28.04 Mil.
BriaCell Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics  (NAS:BCTX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BriaCell Therapeutics's PE Ratio for today is calculated as:

BriaCell Therapeutics's share price for today is $2.17.
BriaCell Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.680.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

BriaCell Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (BriaCell Therapeutics) Business Description